296 related articles for article (PubMed ID: 6403793)
1. CV-3988 - a specific antagonist of platelet activating factor (PAF).
Terashita Z; Tsushima S; Yoshioka Y; Nomura H; Inada Y; Nishikawa K
Life Sci; 1983 Apr; 32(17):1975-82. PubMed ID: 6403793
[TBL] [Abstract][Full Text] [Related]
2. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo.
Terashita Z; Imura Y; Takatani M; Tsushima S; Nishikawa K
J Pharmacol Exp Ther; 1987 Jul; 242(1):263-8. PubMed ID: 3612533
[TBL] [Abstract][Full Text] [Related]
3. Specific inhibition of PAF-acether-induced platelet activation by BN 52021 and comparison with the PAF-acether inhibitors kadsurenone and CV 3988.
Nunez D; Chignard M; Korth R; Le Couedic JP; Norel X; Spinnewyn B; Braquet P; Benveniste J
Eur J Pharmacol; 1986 Apr; 123(2):197-205. PubMed ID: 3086108
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of binding of the platelet-activating factor AGEPC to platelets by the AGEPC analog rac-3-(N-n-octadecylcarbamoyloxy)-2-methoxypropyl 2-thiazolioethyl phosphate (CV-3988).
Valone FH
Biochem Biophys Res Commun; 1985 Jan; 126(1):502-8. PubMed ID: 3970703
[TBL] [Abstract][Full Text] [Related]
5. Effects of CV-3988, an antagonist of platelet-activating factor (PAF), on washed rabbit platelets.
Cox CP
Thromb Res; 1986 Jan; 41(2):211-22. PubMed ID: 2421432
[TBL] [Abstract][Full Text] [Related]
6. Action mechanism of the platelet aggregation inducer and inhibitor from Echis carinatus snake venom.
Teng CM; Ma YH; Ouyang CH
Biochim Biophys Acta; 1985 Jul; 841(1):8-14. PubMed ID: 3926005
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological properties of YM461, a new orally active platelet-activating factor antagonist.
Yamada T; Saito M; Mase T; Hara H; Nagaoka H; Murase K; Tomioka K
Lipids; 1991 Dec; 26(12):1179-83. PubMed ID: 1668114
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K
J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
[TBL] [Abstract][Full Text] [Related]
9. CV3988 inhibits in vivo platelet aggregation induced by PAF-acether and collagen.
Robertson DN; Smith GM
Eur J Pharmacol; 1986 Apr; 123(1):91-7. PubMed ID: 3709663
[TBL] [Abstract][Full Text] [Related]
10. Platelet-activating factor in the inflammatory exudate in the anaphylactic phase of allergic inflammation in rats.
Watanabe M; Ohuchi K; Sugidachi A; Hirasawa N; Hayashi Y; Tsurufuji S
Int Arch Allergy Appl Immunol; 1987; 84(4):396-403. PubMed ID: 3119503
[TBL] [Abstract][Full Text] [Related]
11. Inhibition by CV-3988 of the binding of [3H]-platelet activating factor (PAF) to the platelet.
Terashita Z; Imura Y; Nishikawa K
Biochem Pharmacol; 1985 May; 34(9):1491-5. PubMed ID: 2986648
[TBL] [Abstract][Full Text] [Related]
12. Biological effect of orally active platelet-activating factor receptor antagonist SM-10661.
Komuro Y; Imanishi N; Uchida M; Morooka S
Mol Pharmacol; 1990 Sep; 38(3):378-84. PubMed ID: 2402227
[TBL] [Abstract][Full Text] [Related]
13. Platelet-activating factor (PAF) inhibitory profile of KO-286011 on blood platelets in vitro and in vivo.
Ostermann G; Hofmann B; Kertscher HP; Till U
Naunyn Schmiedebergs Arch Pharmacol; 1990 Dec; 342(6):713-8. PubMed ID: 2096302
[TBL] [Abstract][Full Text] [Related]
14. Derivatives of 2-methylenepropane-1,3-diol as new antagonists of platelet activating factor.
Grue-Sørensen G; Nielsen IM; Nielsen CK
J Med Chem; 1988 Jun; 31(6):1174-8. PubMed ID: 3373485
[TBL] [Abstract][Full Text] [Related]
15. Platelet-activating factor-induced aggregation of human platelets specifically inhibited by triazolobenzodiazepines.
Kornecki E; Ehrlich YH; Lenox RH
Science; 1984 Dec; 226(4681):1454-6. PubMed ID: 6150550
[TBL] [Abstract][Full Text] [Related]
16. trans-2,5-Bis-(3,4,5-trimethoxyphenyl)tetrahydrofuran. An orally active specific and competitive receptor antagonist of platelet activating factor.
Hwang SB; Lam MH; Biftu T; Beattie TR; Shen TY
J Biol Chem; 1985 Dec; 260(29):15639-45. PubMed ID: 2999126
[TBL] [Abstract][Full Text] [Related]
17. Antagonists of PAF-acether do not suppress thrombin-induced aggregation of ADP-deprived and aspirin-treated human platelets.
Adnot S; Joseph D; Vargaftig BB
Agents Actions; 1987 Jun; 21(1-2):195-202. PubMed ID: 3115070
[TBL] [Abstract][Full Text] [Related]
18. Inhibition by ticlopidine of Paf-acether-induced in vitro aggregation of rabbit and human platelets.
Lalau Keraly C; Delautier D; Delabassee D; Chignard M; Benveniste J
Thromb Res; 1984 Jun; 34(6):463-71. PubMed ID: 6740569
[TBL] [Abstract][Full Text] [Related]
19. Is platelet activating factor (PAF) a mediator of endotoxin shock?
Terashita Z; Imura Y; Nishikawa K; Sumida S
Eur J Pharmacol; 1985 Feb; 109(2):257-61. PubMed ID: 3996473
[TBL] [Abstract][Full Text] [Related]
20. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.
Imanishi N; Murakami-Uchida M; Koike H; Natsume Y; Morooka S
Arzneimittelforschung; 1994 Mar; 44(3):317-22. PubMed ID: 8192697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
